Article

Requirement of c-Myb for p210BCR/ABL-dependent transformation of hematopoietic progenitors and leukemogenesis

Department of Cancer Biology, and Kimmel Cancer Center, Thomas Jefferson University Medical College, Philadelphia, PA 19107, USA.
Blood (Impact Factor: 10.43). 06/2008; 111(9):4771-9. DOI: 10.1182/blood-2007-08-105072
Source: PubMed

ABSTRACT The c-Myb gene encodes a transcription factor required for proliferation and survival of normal myeloid progenitors and leukemic blast cells. Targeting of c-Myb by antisense oligodeoxynucleotides has suggested that myeloid leukemia blasts (including chronic myelogenous leukemia [CML]-blast crisis cells) rely on c-Myb expression more than normal progenitors, but a genetic approach to assess the requirement of c-Myb by p210(BCR/ABL)-transformed hematopoietic progenitors has not been taken. We show here that loss of a c-Myb allele had modest effects (20%-28% decrease) on colony formation of nontransduced progenitors, while the effect on p210(BCR/ABL)-expressing Lin(-) Sca-1(+) and Lin(-) Sca-1(+)Kit(+) cells was more pronounced (50%-80% decrease). Using a model of CML-blast crisis, mice (n = 14) injected with p210(BCR/ABL)-transduced p53(-/-)c-Myb(w/w) marrow cells developed leukemia rapidly and had a median survival of 26 days, while only 67% of mice (n = 12) injected with p210(BCR/ABL)-transduced p53(-/-)c-Myb(w/d) marrow cells died of leukemia with a median survival of 96 days. p210(BCR/ABL)-transduced c-Myb(w/w) and c-Myb(w/d) marrow progenitors expressed similar levels of the c-Myb-regulated genes c-Myc and cyclin B1, while those of Bcl-2 were reduced. However, ectopic Bcl-2 expression did not enhance colony formation of p210(BCR/ABL)-transduced c-Myb(w/d) Lin(-)Sca-1(+)Kit(+) cells. Together, these studies support the requirement of c-Myb for p210(BCR/ABL)-dependent leukemogenesis.

0 Followers
 · 
109 Views
  • Source
    • "Interestingly, two of them (Sp1 and CEBPa) are mainly involved in the regulation of gene expression but, more importantly, the other two (c-myb and MZF-1) are typically linked to the hematopoietic system. In fact, c-myb is required for regulating the proliferation and survival of normal myeloid progenitors and leukemic blast cells, while MZF-1 is usually associated with the differentiation of the hematopoietic stem cells (Lidonnici et al., 2008; Morris et al., 1995). Our chromatin immunoprecipitation experiments showed that the four selected transcription factors were only partially recruited to PLC-b1 promoter before the start of epigenetic therapy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The roles of phosphoinositide-specific phospholipase C (PLC) have been extensively investigated in diverse cell lines and pathological conditions. Among the PLC isozmes, primary PLCs, PLC-β and PLC-γ, are directly activated by receptor activation, unlike other secondary PLCs (PLC-ɛ, PLC-δ1, and PLC-η1). PLC-β isozymes are activated by G protein couple receptor and PLC-γ isozymes are activated by receptor tyrosine kinase (RTK). Primary PLCs are differentially expressed in different tissues, suggesting their specific roles in diverse tissues and regulate a variety of physiological and pathophysiological functions. Thus, dysregulation of phospholipases contributes to a number of human diseases and primary PLCs have been identified as therapeutic targets for prevention and treatment of diseases. Here we review the roles of primary PLCs in physiology and their impact in pathology.
    08/2013; 53. DOI:10.1016/j.jbior.2013.08.003
  • Source
    • "In particular, MDS patients responding to azacitidine therapy were reported to show a specific recruitment to PI- PLCb1 promoter of myeloid zinc finger (MZF)-1, but not c-myb. This is particularly appealing, since MZF-1 plays a role in myeloid differentiation (Morris et al., 1995), whereas c-myb is specifically associated with hematopoietic stem cell proliferation (Lidonnici et al., 2008), therefore confirming the involvement of PI-PLCb1 in azacitidine-induced myeloid differentiation (Fig. 1). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Myelodysplastic syndromes (MDS), clonal hematopoietic stem-cell disorders mainly affecting older adult patients, show ineffective hematopoiesis in one or more of the lineages of the bone marrow. Most MDS are characterized by anemia, and a number of cases progresses to acute myeloid leukemia (AML). Indeed, the molecular mechanisms underlying the MDS evolution to AML are still unclear, even though the nuclear signaling elicited by PI-PLCβ1 has been demonstrated to play an important role in the control of the balance between cell cycle progression and apoptosis in MDS cells. Here we review both the role of epigenetic therapy on PI-PLCβ1 promoter and the changes in PI-PLCβ1 expression in MDS patients treated for anemia.
    09/2012; 53(1). DOI:10.1016/j.jbior.2012.09.009
  • [Show abstract] [Hide abstract]
    ABSTRACT: The transcription factor MYB has a key role as a regulator of stem and progenitor cells in the bone marrow, colonic crypts and a neurogenic region of the adult brain. It is in these compartments that a deficit in MYB activity leads to severe or lethal phenotypes. As was predicted from its leukaemogenicity in several animal species, MYB has now been identified as an oncogene that is involved in some human leukaemias. Moreover, recent evidence has strengthened the case that MYB is activated in colon and breast cancer: a block to MYB expression is overcome by mutation of the regulatory machinery in the former disease and by oestrogen receptor-alpha (ERalpha) in the latter.
    Nature Reviews Cancer 08/2008; 8(7):523-34. DOI:10.1038/nrc2439 · 29.54 Impact Factor
Show more

Preview